T1	Date 12 16	2019
T2	PROC 44 91	Estudio para evaluar la eficacia y la seguridad
T3	CHEM 95 104	dupilumab
#1	AnnotatorNotes T3	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	LIVB 108 125	pacientes adultos
T5	Age 118 125	adultos
T6	DISO 130 150	penfigoide ampolloso
#2	AnnotatorNotes T6	C0030805; Bullous pemphigoid; Disease or Syndrome
T7	PROC 171 280	Estudio multicéntrico, aleatorizado, con doble enmascaramiento, controlado con placebo y con grupos paralelos
T8	PROC 286 320	evaluar la eficacia y la seguridad
T9	CHEM 324 333	dupilumab
#3	AnnotatorNotes T9	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	LIVB 337 354	pacientes adultos
T11	Age 347 354	adultos
T12	DISO 359 379	penfigoide ampolloso
#4	AnnotatorNotes T12	C0030805; Bullous pemphigoid; Disease or Syndrome
T13	DISO 404 424	penfigoide ampolloso
#5	AnnotatorNotes T13	C0030805; Bullous pemphigoid; Disease or Syndrome
T14	DISO 432 464	afección cutánea autoinmunitaria
T15	DISO 500 508	ampollas
#6	AnnotatorNotes T15	C0005758; Bulla; Finding
T16	ANAT 519 526	líquido
T17	DISO 551 571	Penfigoide ampolloso
#7	AnnotatorNotes T17	C0030805; Bullous pemphigoid; Disease or Syndrome
T18	DISO 572 575	(PA
T19	LIVB 609 618	pacientes
#8	AnnotatorNotes T19	C0030705; Patients; Patient or Disabled Group
T20	DISO 635 659	manifestaciones clínicas
#9	AnnotatorNotes T20	C0037088; Signs and Symptoms; Sign or Symptom
T21	DISO 663 665	PA
#10	AnnotatorNotes T21	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T22	DISO 675 682	prurito
#11	AnnotatorNotes T22	C0033774; Pruritus; Sign or Symptom
T23	DISO 684 692	ampollas
#12	AnnotatorNotes T23	C0005758; Bulla; Finding
T24	DISO 695 742	placas eritematosas, eccematosas o urticarianas
T25	PROC 752 781	isitas de selección e inicial
T26	LIVB 806 819	participantes
T27	PROC 845 900	confirmación histológica, inmunopatológica y serológica
T28	DISO 905 907	PA
#13	AnnotatorNotes T28	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T29	PROC 1181 1184	NRS
T30	DISO 1216 1223	prurito
#14	AnnotatorNotes T30	C0033774; Pruritus; Sign or Symptom
T31	LIVB 1241 1264	Personas de ambos sexos
T32	Age 1269 1287	entre 18 y 90 años
T33	PROC 1294 1313	visita de selección
T34	PROC 1346 1379	valoración funcional de Karnofsky
T35	PROC 1386 1405	visita de selección
T36	PROC 1477 1486	protocolo
#15	AnnotatorNotes T36	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T37	DISO 1526 1536	penfigoide
#16	AnnotatorNotes T37	C0030805; Bullous pemphigoid; Disease or Syndrome
T38	Neg_cue 1537 1549	distintos al
T39	DISO 1550 1560	PA clásico
#17	AnnotatorNotes T39	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T40	DISO 1573 1600	PA de las membranas mucosas
#18	AnnotatorNotes T40	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T41	DISO 1605 1646	penfigoide cicatricial de Brunsting Perry
T42	DISO 1651 1671	penfigoide anti-p200
T43	DISO 1676 1709	epidermólisis ampollosa adquirida
#19	AnnotatorNotes T43	C0079293; Epidermolysis Bullosa Acquisita; Disease or Syndrome
T44	DISO 1715 1717	PA
#20	AnnotatorNotes T44	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T45	DISO 1722 1736	pénfigo vulgar
#21	AnnotatorNotes T45	C0030809; Pemphigus Vulgaris; Disease or Syndrome | C4303496; Pemphigus of vulva; Disease or Syndrome
T46	LIVB 1755 1764	Pacientes
#22	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	PROC 1786 1798	tratamientos
#23	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	DISO 1825 1827	PA
#24	AnnotatorNotes T48	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T49	CHEM 1837 1893	inhibidores de la enzima convertidora de la angiotensina
#25	AnnotatorNotes T49	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T50	CHEM 1895 1907	penicilamina
#26	AnnotatorNotes T50	C0030817; penicillamine; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T51	CHEM 1909 1919	furosemida
#27	AnnotatorNotes T51	C0016860; furosemide; Organic Chemical · Pharmacologic Substance
T52	CHEM 1921 1931	fenacetina
#28	AnnotatorNotes T52	C0031364; phenacetin; Hazardous or Poisonous Substance · Organic Chemical
T53	CHEM 1934 1972	inhibidor de la dipeptidil peptidasa-4
T54	Neg_cue 1978 1980	no
T55	Negated 2001 2014	dosis estable
T56	CHEM 2024 2036	medicamentos
#29	AnnotatorNotes T56	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T57	Duration 2045 2067	un mínimo de 4 semanas
T58	PROC 2133 2144	tratamiento
#30	AnnotatorNotes T58	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T59	CHEM 2152 2185	antagonista de la IL-4 o la IL-13
T60	CHEM 2192 2201	dupilumab
#31	AnnotatorNotes T60	C3660996; dupilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T61	CHEM 2203 2215	tralokinumab
T62	CHEM 2218 2230	lebrikizumab
T63	PROC 2235 2246	Tratamiento
T64	Duration 2288 2301	las 2 semanas
T65	PROC 2318 2332	visita inicial
T66	PROC 2337 2348	Tratamiento
T67	Route 2371 2378	tópicos
T68	CHEM 2406 2434	inhibidor de la calcineurina
T69	Route 2435 2441	tópico
T70	CHEM 2444 2455	crisaborole
T71	Route 2456 2462	tópico
T72	Duration 2471 2489	la semana anterior
T73	PROC 2514 2525	Tratamiento
#32	AnnotatorNotes T73	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T74	CHEM 2530 2547	inmunomoduladores
#33	AnnotatorNotes T74	C1527392; Immunomodulators; Immunologic Factor · Pharmacologic Substance
T75	CHEM 2548 2579	inmunodepresores no esteroideos
T76	Neg_cue 2565 2567	no
T77	Negated 2568 2579	esteroideos
T78	CHEM 2589 2610	micofenolato mofetilo
#34	AnnotatorNotes T78	C0209368; mycophenolate mofetil; Organic Chemical · Pharmacologic Substance
T79	CHEM 2612 2623	azatioprina
#35	AnnotatorNotes T79	C0004482; azathioprine; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T80	CHEM 2626 2637	metotrexato
#36	AnnotatorNotes T80	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T81	Duration 2647 2660	las 4 semanas
T82	PROC 2696 2707	Tratamiento
#37	AnnotatorNotes T82	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T83	CHEM 2712 2723	biofármacos
T84	DISO 2737 2739	PA
#38	AnnotatorNotes T84	C0001339; Pancreatitis, Acute; Disease or Syndrome | C0162323; Polyarthritis; Disease or Syndrome
T85	CHEM 2749 2770	fármaco citorreductor
T86	CHEM 2794 2803	rituximab
#39	AnnotatorNotes T86	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T87	Duration 2813 2825	los 12 meses
T88	PROC 2872 2899	cifra de linfocitos y CD19+
T89	Date 2944 2953	más tarde
T90	CHEM 2963 2974	biofármacos
T91	CHEM 2985 3004	inhibidores de IL-5
T92	CHEM 3005 3017	benralizumab
T93	CHEM 3020 3031	mepolizumab
#40	AnnotatorNotes T93	C0969324; mepolizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T94	Duration 3042 3057	las 5 semividas
T95	Duration 3075 3089	las 16 semanas
T96	CHEM 3151 3166	Inmunoglobulina
#41	AnnotatorNotes T96	C0021027; Immunoglobulins; Amino Acid, Peptide, or Protein · Immunologic Factor
T97	Route 3167 3178	intravenosa
T98	Duration 3187 3201	las 16 semanas
T99	PROC 3303 3312	protocolo
#42	AnnotatorNotes T99	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T100	PROC 824 831	estudio
T101	PROC 1051 1056	BPDAI
T102	PROC 1058 1095	Bullous Pemphigoid Disease Area Index
T103	CHEM 2251 2268	corticoesteroides
T104	Route 2269 2279	sistémicos
T105	CHEM 2353 2370	corticoesteroides
T106	Dose 2382 2405	potencia media o mayor,
T107	PROC 1009 1049	índice del área del penfigoide ampolloso
T108	PROC 1164 1179	escala numérica
T109	PROC 1104 1111	visitas
T110	DISO 989 999	enfermedad
T111	PROC 928 934	visita
T112	Negated 1550 1560	PA clásico
T113	Negated 1981 1996	hayan mantenido
T114	Dose 2001 2014	dosis estable
T115	PROC 2080 2086	visita
T116	PROC 2495 2501	visita
T117	PROC 2677 2683	visita
T118	PROC 2842 2848	visita
T119	PROC 3106 3112	visita
T120	PROC 3218 3224	visita
T121	Quantifier_or_Qualifier 774 781	inicial
T122	Quantifier_or_Qualifier 935 942	inicial
T123	Result_or_Value 962 966	>=24
T124	CONC 1009 1049	índice del área del penfigoide ampolloso
T125	Quantifier_or_Qualifier 1127 1134	inicial
T126	Result_or_Value 1154 1157	>=4
T127	CONC 1171 1179	numérica
T128	CONC 1230 1236	inicio
T129	Result_or_Value 1333 1339	>=50 %
T130	CONC 1438 1460	criterios de inclusión
T131	Quantifier_or_Qualifier 1737 1749	concomitante
T132	Quantifier_or_Qualifier 2325 2332	inicial
T133	Quantifier_or_Qualifier 2379 2404	de potencia media o mayor
T134	Quantifier_or_Qualifier 2502 2509	inicial
T135	Quantifier_or_Qualifier 2568 2579	esteroideos
T136	Quantifier_or_Qualifier 2684 2691	inicial
T137	Quantifier_or_Qualifier 2724 2733	dirigidos
T138	Quantifier_or_Qualifier 2849 2856	inicial
T139	Result_or_Value 2900 2923	retorne a la normalidad
T140	Quantifier_or_Qualifier 3113 3120	inicial
T141	Quantifier_or_Qualifier 3225 3232	inicial
T142	CONC 3264 3286	criterios de exclusión
T143	Patient 108 125	pacientes adultos
T144	Patient 337 354	pacientes adultos
T145	Patient 609 618	pacientes
T146	Patient 806 819	participantes
T147	Patient 1241 1264	Personas de ambos sexos
T148	Patient 1755 1764	Pacientes
T149	History_of 2133 2144	tratamiento
T150	History_of 2152 2185	antagonista de la IL-4 o la IL-13
T151	History_of 2192 2201	dupilumab
T152	History_of 2203 2215	tralokinumab
T153	History_of 2218 2230	lebrikizumab
